The approval marks the first and only treatment for geographic atrophy, a leading cause of blindness.
Syfovre and Izervay must not be used with other geographic atrophy drugs for commercial members, starting Nov. 24.
Pegcetacoplan (Geographic Atrophy) (Local) (Monograph). Drug class: Macular Degeneration Agents. Medically reviewed by Drugs.com on Jun 10
Until earlier this year, there were no Food and Drug Administration (FDA) approved treatments available to patients with geographic atrophy. In February 2024, Syfovre (pegcetacoplan) became the first FDA-approved treatment for geographic atrophy, and now, the FDA has approved a second medication, Izervay (avacincaptad pegol).
The Geographic Atrophy market in the United States is estimated to be ~$1 billion. Which therapies are leading the geographic atrophy market? Immune response-
drugs, over-the-counter medicines and natural products. This material is Discover a treatment option for Geographic Atrophy. Close.
effect increased over time. The drug works by inhibiting parts of the body's inflammatory response that contribute to geographic atrophy. SYFOVRE is
3.3 No treatment for geographic atrophy Geographic atrophy involving the fovea is responsible for approximately 10% of all AMD-related visual loss of 20/200 or
Izervay was shown to slow progression of geographic atrophy, a leading cause of irreversible blindness.
Comments